Multidrug-resistant (MDR) tuberculosis is a major health threat globally. Nearly half a million MDR TB cases are estimated to occur worldwide annually, including cases that are extensively drug-resistant (XDR).

While MDR and XDR TB are relatively rare in the U.S., their treatment comes at a terrible price – it is very expensive, takes a long time, disrupts lives, and has potentially life-threatening side effects.

The Outsized Financial Toll of MDR and XDR TB
Cost increases with greater resistance:

![Diagram showing cost breakdown for TB, MDR TB, and XDR TB treatment]

A Major Human Cost
Of those treated for drug-resistant TB:

- 9% Die During Treatment
- 27% Stop Working
- 73% Hospitalized
- 37% Require Home Isolation

Severe Treatment Side Effects

- Depression/Psycho: 19%
- Hearing Impairment: 13%
- Hepatitis: 13%
- Kidney Impairment: 11%
- Loss of Mobility: 8%
- Vision Impairment: 7%
- Seizures: 1%

Preventing and Controlling MDR and XDR TB in the U.S. Requires:

**Better Treatment Options**

**Rapid Diagnosis**

**Expert Treatment of Every TB Case**

**Improving Global TB Diagnosis and Treatment**

Footnotes:

1 Multidrug-resistant TB is resistant to at least two of the best and most important anti-TB drugs (isoniazid and rifampin).

2 Extensively drug-resistant TB is resistant to isoniazid and rifampin among first-line drugs, and resistant to any fluoroquinolone and at least one second-line injectable drug.


March 2014

http://www.cdc.gov/nchhstp/newsroom